These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18336596)

  • 21. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Dandekar DS; Lokeshwar BL
    Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
    Niu YN; Xin DQ; He ZS; Zhou LQ; Pan BN; Na YQ; Guo YL
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):394-7. PubMed ID: 15854351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
    Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS
    Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
    Niu ZH; Wang Y; Chun B; Li CX; Wu L
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1337-44. PubMed ID: 23740447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
    Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
    Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
    BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.
    Rocchi P; Jugpal P; So A; Sinneman S; Ettinger S; Fazli L; Nelson C; Gleave M
    BJU Int; 2006 Nov; 98(5):1082-9. PubMed ID: 16879439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
    Zoubeidi A; Chi K; Gleave M
    Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
    Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
    BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
    Tang Y; Liu F; Zheng C; Sun S; Jiang Y
    J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
    Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
    Tolcher AW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):67-70. PubMed ID: 11685732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    Van Laar ES; Weitman S; MacDonald JR; Waters SJ
    Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.